CTRI/2022/08/044792招募中4 期
A Phase IV interventional post approval trial to assess the safety of intravitreal aflibercept for the treatment of diabetic macular edema (DME) in patients in India. - VISION AF
试验速览
- 阶段
- 4 期
- 状态
- 招募中
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Female or male adult participant >=18 years of age, with type 1 or 2 diabetes mellitus.
- •2. Participant must have DME secondary to diabetes mellitus, involving the centre of the macula (defined as the area of the centre subfield of OCT) in the study eye.
- •3. Decrease in vision, determined to be primarily the result of DME in the study eye.
- •4. Retinal thickness of >=300 µm in the study eye, as assessed by OCT.
- •5. BCVA ETDRS letter score of 73 to 24 (i.e., VA of 20/50 to 20/320) or equivalent in the study eye.
- •6. Participant for whom the decision to initiate treatment with IVT aflibercept has been
- •made by the treating Investigator/Physician.
- •7. Willing and able to comply with clinic visits and study-related procedures.
- •8. Provide a signed ICF prior to any study procedures.
排除标准
- •1. Having any contraindications to the use of IVT aflibercept as listed in the local prescribing information (i.e., ocular or periocular infection, active severe intraocular inflammation, and known hypersensitivity to aflibercept or to any of the excipients).
- •2. History of vitreoretinal surgery and/or scleral buckling in the study eye.
- •3. Ocular conditions with a poorer prognosis in the fellow eye than in the study eye.
- •4. Known history of allergy to fluorescein used in fluorescein angiography, and indocyanine green used in indocyanine green angiography. As indocyanine green dye contains iodine, so severe allergic reactions are possible in patients allergic to iodine.
- •5. Any laser photocoagulation (panretinal or macular) in the study eye within the last 3
- •months of Day 1.
- •6. Any cataract surgery in the study eye within the last 3 months of Day 1.
- •7. Any intraocular surgery in the study eye within the last 3 months of Day 1.
- •8. Received previous/ prior treatment as mentioned below:
- •a) Received anti-VEGF drugs in the study eye (pegaptanib sodium, bevacizumab, ranibizumab, etc., including aflibercept) within the last 3 months of Day 1.
- •b) Received IVT dexamethasone or triamcinolone in the study eye within the last 3 months of Day 1.
- •c) Received intraocular or periocular corticosteroids in the study eye within the last 4
- •months of Day 1.
- •d) Had fluocinolone implant in the study eye within the last 3 years of Day 1.
- •e) Had dexamethasone implant in the study eye within the last 6 months of Day 1.
- •f) systemic anti-angiogenic agents within 6 months of Day 1.
- •9. Uncontrolled glaucoma in the study eye (patient who has had filtration surgery in the
- •past, or likely to need filtration surgery in the future).
- •10. IOP >=25 mm Hg in the study eye.
- •11. Only 1 functional eye even if that eye is otherwise eligible for the study.
- •12. Ocular media of insufficient quality to obtain fundus and OCT images.
- •13. Uncontrolled DM in the opinion of the investigator.
- •14. Uncontrolled blood pressure (BP) (defined as systolic >160 mm Hg or diastolic >95 mm Hg while patient is sitting).
- •15. History of cerebrovascular accident or MI within 6 months of Day 1.
- •16. Renal failure, dialysis, or history of renal transplant.
- •17. Participated in an investigational study within 30 days prior to screening visit that
- •involved treatment with any drug (excluding vitamins and minerals) or device.
- •18. Pregnant or breast-feeding women.
- •19. Sexually active men or WOCBPa who are unwilling to practice adequate contraception
- •during the study (adequate contraceptive measures include stable use of oral contraceptives or other prescription pharmaceutical contraceptives for 2 or more menstrual cycles prior to screening; intrauterine device [IUD]; bilateral tubal ligation; vasectomy; condom plus contraceptive sponge, foam, or jelly or diaphragm plus
- •contraceptive sponge, foam, or jelly).
- •20. WOCBPa with either a positive pregnancy test result or no pregnancy test at baseline.
研究者
相似试验
招募中
4 期
Trial to evaluate vericiguat therapy in heart failure patients.CTRI/2022/11/047636Bayer Zydus Pharma Private Limited
进行中（未招募）
1 期
Study comparing Treatment with Alluzience vs Reconstituted toxin (STAR)Moderate to severe glabellar lines (GL).MedDRA version: 21.1Level: LLTClassification code 10052609Term: Glabellar frown linesSystem Organ Class: 100000004858EUCTR2021-004748-62-DEQ-Med AB, part of the Galderma Group150
进行中（未招募）
不适用
Study about the high flow and conventional oxigen therapy in patients with severe acute respiratory failure.EUCTR2012-001671-36-ESFundación para la Investigación Biomédica
已完成
4 期
Parenting Eating and Activity for Child HealthChild overweightDiet and Nutrition - Other diet and nutrition disordersACTRN12606000120572Flinders University168
招募中
3 期
Outpatient Ifosfamide, Etoposide plus Rituximab (R-IE) for salvage in patients > 60 years with relapsed or refractory CD20 positive diffuse large B-cell lymphoma who are not candidates for stem cell transplant studyRelapsed or refractory CD20 positive diffuse large B-cell lymphomaCancer - Lymphoma (non Hodgkin's lymphoma) - High grade lymphomaACTRN12606000373572Roche40